el desarrollo de hipercloremia durante el tratamiento es un hallazgo habitual en estos pacientes ( 94%).   Sin embargo. que se producen son fundamentalmente la hipernatremia, la hipercloremia, El tratamiento clásico era la administración de vasopresina endovenosa. por lo que el desarrollo de hipercloremia durante el tratamiento es un hallazgo habitual en estos pacientes ( 94%).   Sin embargo, existe.
|Published (Last):||18 April 2016|
|PDF File Size:||12.79 Mb|
|ePub File Size:||7.64 Mb|
|Price:||Free* [*Free Regsitration Required]|
Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name.
Pneumonia AND sponsor name. How to search [pdf]. For these items you should use the filters and not add them to your search terms in the text field. Trials with results Trials without results Clear advanced search filters.
Review by the Competent Authority or Ethics Committee in the country concerned. EU Clinical Trials Register. Both Female Only Male Only.
IMP with orphan designation in the indication. Trials with results Trials without results. Clear advanced search filters. Date on which this record was first entered in the EudraCT database:.
Title of the trial for lay people, in easily understood, i. Controlled, international study conducted in several centres on the safety and therapeutic effect of a Tratamkento HES solution versus an trataamiento solution in patients undergoing elective abdominal surgery. The IMP has been designated in this indication as an orphan drug in the Community.
Committee on Advanced therapies CAT has issued a classification for this product. Combination product that includes a device, but does not involve an Advanced Therapy. Hypovolaemia due to acute blood loss in elective abdominal surgery. Decreased blood volume due to acute blood loss during scheduled surgery of the abdomen.
Manifestaciones clínicas by Fernando Marein Reyes on Prezi
Further investigation of safety and efficacy of the applied products. Difference in mean estimated glomerular filtration rate eGFR between the two treatment groups, calculated from the highest Cystatin-C level measured during post-operative days POD Cystatin-C levels will be determined on POD Safety – Renal function: C-reactive protein C-RP – Adverse events: T0, T1 at least q 30 minT2-T4 vol guide: T0, T2, T3 S Elyte: T0, T2, T3 Maj compl: T7, T8 Balance de fluidos: T0, T2, T3 Electrolitos: T0, T2, T3 Compl myores: The trial involves single site in the Member State concerned.
Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. POD7 or hospital discharge, whatever occurs first for last patient. Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March this question read: An answer of yes could have included women of child bearing potential whether or not they would be using contraception.
TRASTORNOS DEL CLORO by Daniel Garzon Luna on Prezi
The answer should therefore be understood in that context. This trial was recorded in the database on Plans for hiperclotemia or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition. Not different from the expected normal treatment of the condition.